APP and Alzheimer disease: Despite the superior efficacy of epigallocatechin, the fact that it enhanced APP-cleavage dependent luciferase expression at 10 μM suggested increased amyloidogenic processing at high concentrations making it unsuitable for consideration as a potential intervention for AD.